yingweiwo

Bromhexine HCl

Cat No.:V12109 Purity: ≥98%
Bromhexine HCl is a potent and specific TMPRSS2 protease inhibitor (antagonist) with IC50 of 0.75 μM.
Bromhexine HCl
Bromhexine HCl Chemical Structure CAS No.: 611-75-6
Product category: New1
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5g
10g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
Bromhexine HCl is a potent and specific TMPRSS2 protease inhibitor (antagonist) with IC50 of 0.75 μM. Bromhexine HCl can prevent and control SARS-CoV-2 infection. Bromhexine HCl is an autophagy activator. Bromhexine HCl is a mucolytic cough suppressant with potential usefulness in research into a variety of respiratory diseases.
Biological Activity I Assay Protocols (From Reference)
ln Vitro
The natural expression of TMPRSS2 in LNCaP and C4-2B cells was dramatically inhibited by HGF-induced invasion when exposed to 250μM of bromhexine hydrochloride (BHH) for a 24-hour period [1]. When bromhexine hydrochloride was added to LNCaP, DU145, PC3, or HepG2 cells at doses ranging from 0 μM to 250 μM for 48 hours, no appreciable toxicity was seen. DU145 cell proliferation is not significantly inhibited or induced to die upon exposure to bromhexine hydrochloride [1]. HIV-1 infection of dendritic cells is inhibited by bromhexine hydrochloride (20 μM; 48 hours) [4].
ln Vivo
In mice of the wild-type C57BL/6 strain, bromhexine hydrochloride (30 mg/kg; i.p.; three times weekly for five weeks) dramatically decreased the incidence of distant metastases to the liver and lungs from 55% in vehicle-treated animals to 20% in PIN (prostatic intraepithelial neoplasia) in TRAMP mice. Compared to TRAMP mice treated with vehicle, mice treated with bromhexine hydrochloride typically had prostates that were significantly bigger [1].
References

[1]. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014 Nov;4(11):1310-25.

[2]. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017 Nov;142:1-10.

[3]. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020 Jul;157:104837.

[4]. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620.

Additional Infomation
Bromhexine hydrochloride is a hydrochloride resulting from the reaction of equimolar amounts of bromhexine and hydrogen chloride. It is used as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum). It has a role as a mucolytic. It contains a bromhexine(1+).
Bromhexine Hydrochloride is the hydrochloride salt form of bromhexine, a secretolytic, with mucolytic activity. Upon administration, bromhexine increases lysosomal activity and enhances hydrolysis of acid mucopolysaccharide polymers in the respiratory tract. This increases the production of serous mucus in the respiratory tract, which makes the phlegm thinner and decreases mucus viscosity. This contributes to its secretomotoric effect, and allows the cilia to more easily transport the phlegm out of the lungs. This clears mucus from the respiratory tract and may aid in the treatment of respiratory disorders associated with abnormal viscid mucus, excessive mucus secretion and impaired mucus transport.
A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
See also: Bromhexine (has active moiety).
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C14H21BR2CLN2
Molecular Weight
412.5909
Exact Mass
409.975
CAS #
611-75-6
Related CAS #
Bromhexine-d3 hydrochloride
PubChem CID
5702220
Appearance
White to off-white solid powder
Boiling Point
441.5ºC at 760 mmHg
Melting Point
240-244 °C
Flash Point
220.8ºC
LogP
5.941
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
2
Rotatable Bond Count
3
Heavy Atom Count
19
Complexity
256
Defined Atom Stereocenter Count
0
InChi Key
UCDKONUHZNTQPY-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H20Br2N2.ClH/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17;/h7-8,12H,2-6,9,17H2,1H3;1H
Chemical Name
2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline;hydrochloride
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO : ~20 mg/mL (~48.47 mM)
H2O : ~3.33 mg/mL (~8.07 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2 mg/mL (4.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 2: ≥ 2 mg/mL (4.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

View More

Solubility in Formulation 3: 2.22 mg/mL (5.38 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C).


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.4237 mL 12.1186 mL 24.2371 mL
5 mM 0.4847 mL 2.4237 mL 4.8474 mL
10 mM 0.2424 mL 1.2119 mL 2.4237 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • Flubendazole affects HIV-1 infection of DC and microbial killing.(a) Flow cytometry analysis of HIV-1 Gag levels in iDCs on day 4 and day 11 with (triangles) or without (squares) flubendazole or with AZT (inverted triangles) treatment. (b) Data (from three different donors), mean±s.d. (n=3). (c) HIV-1 R5 infected (p24, 250 ng) DCs; intracellular Gag levels at 48 h postinfection in DCs treated with flubendazole (2 μM), fluvoxamine (2 μM), bromhexine (20 μM), niclosamide (0.2 μM) or rapamycin (5 μM) as a control. Values normalized to DC+ HIV-1 infection at 100%. Data, mean±s.d. (n=3). (d) Confocal images showing the localization of adherent invasive E.coli LF82 (green) relative to anti-LAMP1 staining (red) in flubendazole-treated or untreated HeLa cells. (e) Percentage of intracellular E. coli LF82 (green) colocalized with lysosome marker protein LAMP1 (red) in absence or presence of flubendazole from 30 microscopic fields for each of control or treated cells±s.e. Student's unpaired t-test was used to test for statistical significance *P<0.05. [4]. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620.
  • Flubendazole and bromhexine block inflammation-induced tau hyperphosphorylation.(a–c) N2a neuroblastoma cells were transfected with human tau (H-Tau) carrying T231D/S235D disease-associated phosphomimetic mutations and treated with CM (culture supernatant from RAW 264.7 macrophages activated with LPS) for 24 h in the presence or absence of autophagy agonists. Immunoblots for different forms of tau and phosphorylated states of tau: pS202 Tau, tau phosphorylated at Ser-202; pS396/404 Tau, tau hyperphosphorylated at Ser-396 and Ser-404 sites; H-Tau, transfected human tau (detected by Tau12 antibody); T-Tau (total, that is, mouse and human, tau detected by Tau5 antibody). (d) Analysis of phosphorylated tau levels in N2a cells knockdown for Beclin1 and treated with flubendazole. (e) Treatments as in b; lanes and blots as indicated (including human Tau revelaed with Tau12 antibody). (f) Analysis of phosphorylated tau levels in N2a cells knockdown for Beclin1 and treated with bromhexine. (g) Analysis of hyperphosphorylated (pS396/404) tau levels in cells cotransfected with mutant H-Tau (T231D/S235D) and Flag-TFEB in N2a cells. TFEB transfection was detected using anti-Flag antibody. Data, mean±s.e. (n=3); *P<0.05; **P<0.01; ANOVA Tukey's multiple comparison post hoc test or unpaired t-test. ANOVA, analysis of variance.[4]. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620.
Contact Us